Management of thyroid disorders

Postgraduate Medical Journal

Volumn 82, Issue 971, 2006, Pages 552-558

  Premawardhana, L D K E ^a   Lazarus, J H ^b  

^a ANEURIN BEVAN UNIVERSITY HEALTH BOARD   (United Kingdom)

^b UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; ANTITHYROID AGENT; CORTICOSTEROID; LIOTHYRONINE; RADIOACTIVE IODINE; THIONAMIDE; THYROTROPIN; THYROXINE;

AGRANULOCYTOSIS; ARTHRALGIA; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GRAVES DISEASE; HUMAN; HYPOTHYROIDISM; PREGNANCY; REMISSION; REVIEW; SKIN MANIFESTATION; THYROID CARCINOMA; THYROID DISEASE;

ANTITHYROID AGENTS; FEMALE; HUMANS; IODINE RADIOISOTOPES; PREGNANCY; PREGNANCY COMPLICATIONS; THYROID DISEASES;

EID: 33749186002     PISSN: 00325473     EISSN: None     Source Type: Journal    
DOI: 10.1136/pgmj.2006.047290     Document Type: Review

References (43)

1. Weetman AP. Autoimmune thyroid disease; propagation and progression. Eur J Endocrinol 2003;148:1-9.
2. Simmonds MJ, Gough SCL. Genetic insights into disease mechanisms of autoimmunity. Br Med Bull 2005;71:93-113.
3. Tunbridge WM, Evered DC, Hall R, et al. The spectrum of thyroid disease in a community; the Whickham survey. Clin Endocrinol (Oxf) 1977;7:481-93.
4. Vanderpump MP, Tunbridge WM, French JM, et al. The incidence of thyroid disorders in the community; a twenty year follow up of the Whickham survey. Clin Endocrinol (Oxf) 1995;43:55-68.
5. Flynn RWV, MacDonald TM, Morris TM, et al. The thyroid epidemiology, audit and research study: thyroid dysfunction in the general population. J Clin Endocrinol Metab 2004;89:3879-83.
6. Bulow Pedersen I, Knudsen N, Jorgensen T, et al. Large differences in incidences of overt hyper and hypothyroidism associated with a small difference in iodine intake: a prospective comparative register based population survey. J Clin Endocrinol Metab 2002;87:4462-9.
7. Sato K, Okamura K, Hirata T, et al. Immunological and chemical types of reversible hypothyroidism; clinical characteristics and long-term prognosis. Clin Endocrinol 1996;45:519-24.
8. Baloch Z, Carayon P, Conte-Devolx B, et al. Laboratory medicine practice guidelines; Laboratory support for the diagnosis and monitoring of thyroid disease. Thyroid 2003;13:3-126.
9. Walsh JP, Shiels L, Lim EM, et al. Combined levothyroxine/liothyronine treatment does not improve well being, quality of life, or cognitive function compared to thyroxine alone: a randomised controlled trial in patients with primary hypothyroidism. J Clin Endocinol Metab 2003;88:4543-50.
10. The American Thyroid Association, The Endocrine Society, American Association of Clinical Endocrinologists. Joint statement on the US Food and Drug Administration's decision regarding bioequivalence of levothyroxine sodium. Thyroid 2004;14:486.
11. Cooper DS. Drug therapy; antithyroid drugs. N Engl J Med 2005;352:905-17.
12. Weetman AP. Graves' disease. N Engl J Med 2000;347:1232-48.
13. Weetman AP. Graves' hyperthyroidism; how long should antithyroid drug therapy be continued to achieve remission? Nature Clin Pract Endocrinol Metab 2006;2:2-3.
14. Abraham P, Avenell A, Park AM, et al. A systematic review of drug therapy for Graves' hyperthyroidism. Eur J Endocrinol 2005;153:489-98.
15. Schott M, Morgenthaler NG, Fritzen R, et al. Levels of autoantibodies against human TSH receptor predict relapse of hyperthyroidism in Graves' disease. Horm Metab Res 2004;36:92-6.
16. Nedrebo BG, Holm PI, Uhlving S, et al. Predictors of outcome and comparison of different drug regimes for the prevention of relapse of patients with Graves' disease. Eur J Endocrinol 2002;147:583-9.
17. Rondebush CP, Hoye KE, De Groot LJ. Compensated low dose I131 therapy in Graves' disease. Ann Intern Med 1977;17:441-7.
18. Berg G, Michande A, Holmberg E, et al. Clinical outcome of RAI treatment for hyperthyroidism. J Intern Med 1996;239:168-71.
19. Franklyn JA, Maisonneuve P, Sheppard MC, et al. Cancer incidence and mortality after RAI therapy for hyperthyroidism - a population based cohort study. Lancet 1999;353:2111-15.
20. Kraassas GE, Wiersinga W. Thyroid eye disease; current concepts and the EUGOGO perspective. Thyroid International 2005;4:3-21.
21. Cawood T, Moriarty P, O'Shea D. Recent developments in thyroid eye disease. BMJ 2004;329:385-90.
22. Bartalena L, Marcocci C, Pincera A. Graves' ophthalmopathy; a preventable disease? Eur J Endocrinol 2002;146:457-61.
23. Hegedus L, Bonnema SJ, Bennedbaek FN. Management of simple nodular goitre; current status and future perspectives. Endocr Rev 2003;24:102-32.
24. Hegedus L. The thyroid nodule. N Engl J Med 2004;351:1764-71.
25. Singer PA, Cooper DS, Daniels GH, et al. Treatment guidelines for patients with thyroid nodules and well-differentiated thyroid cancer. Arch Intern Med 1996;156:2165-72.
26. Feld S, Garcia M, Baskin HJ, et al. AACE clinical practice guidelines for the diagnosis and management of thyroid nodules. Enodcr Pract 1996;2:78-84.
27. Castro MR, Gharib H. Continuing controversies in the management of thyroid nodules. Ann Intern Med 2005;142:926-31.
28. Martino E, Bartalena L, Bogazzi F, et al. The effects of amiodarone on the thyroid. Endocr Rev 2001;22:240-54.
29. Osman F, Franklyn JA, Sheppard MC, et al. Successful treatment of amiodarone induced thyrotoxicosis. Circulation 2002;105:1275-7.
30. Kirov G, Tredget J, John R, et al. A cross-sectional and a prospective study of thyroid disorders in lithium treated patients. J Affect Disord 2005;87:313-17.
31. Carella C, Mazziotti G, Amato G, et al. Interferon alpha related thyroid disease; pathophysiological, epidemiological and clinical aspects. J Clin Endocrinol Metob 2004;89:3656-61.
32. Haddow JE, Palomaki GE, Allen WC, et al. Maternal thyroid deficiency and subsequent neuropsychological development of the child. N Engl J Med 1999;341:549-55.
33. Kimura M, Amino N, Tamaki H, et al. Gestational thyrotoxicosis and hyperemesis gravidarum; possible role for hCG with higher stimulating activity. Clin Endocrinol (Oxf) 1993;38:345-50.
34. Mandel SJ, Cooper DS. The use of antithyroid drugs in pregnancy and lactation. J Clin Endocrinol Metab 2001;86:2354-9.
35. Laurberg P, Nygaard B, Glinoer D, et al. Guidelines for TSH receptor antibody measurements in pregnancy; results of an evidence-based symposium organised by the European Thyroid Association. Eur J Endocrinol 1998;139:584-6.
36. Lazarus JH. Thyroid disorders associated with pregnancy. Treat Endocrinol 2005;4:31-41.
37. Premawardhana LDKE, Parkes AB, Ammari F, et al. Postpartum thyroiditis and long term thyroid status; influence of thyroid peroxidase antibodies and ultrasound echogenicity. J Clin Endocrinol Metab 2000;85:71-5.
38. Lazarus JH, Premawardhana LDKE. Screening for thyroid disease in pregnancy. J Clin Pathol 2005;58:449-52.
39. Col NF, Surks MI, Daniel GH. Subclinical thyroid disease. JAMA 2004;291:239-43.
40. Gharib H, Tuttle M, Baskin J, et al. Consensus statement: subclinical thyroid dysfunction: A joint statement on the management from the American Association of Clinical Endocrinologists, the American Thyroid Association and the Endocrine Society. J Clin Endocrinol Metab 2005;90:581-6.
41. Gussekloo J, van Exel E, de Crein AJ, et al. Thyroid status, disability and cognitive function and survival in old age. JAMA 2004;292:2591-9.
42. Biondi B, Palmieri EA, Klain M, et al. Subclinical hyperthyroidism; clinical features and treatment options. Eur J Endocrinol 2005;152:1-9.
43. Chopra I. Euthyroid sick syndrome: Is it a misnomer? J Clin Endocrinol Metab 1997;82:329-34.